Recent News
- OncBioMune Announces Compelling Pre-Clinical Data for its CD71-Targeted Chemotherapy, PGT, in Models of Lung, Pancreatic and Ovarian Cancers July 15, 2019
- OncBioMune Announces Initial In Vitro Proof-of-Concept Data for PGT in a Multi-Drug Resistant Ovarian Cancer Model May 30, 2019
- OncBioMune Announces Agreement with CATO BioVentures as a Strategic Investor in Support of CD71-Targeted Therapy for Refractory Cancers May 1, 2019
- Phase 2 Trial of OncBioMune’s Immunotherapy Cancer Vaccine ProscaVax for Prostate Cancer Patients in Active Surveillance Now Open for Enrollment March 19, 2019
- OncBioMune Announces Consulting Agreement with CATO Research LLC for Developing PGT, a Protein Drug Complex Targeting CD71 for Refractory Cancers February 28, 2019
- Dr. Mitesh Borad Joins OncBioMune Scientific Advisory Board January 28, 2019
- OncBioMune Announces Former Puma Biotechnology Executive and Genentech Veteran Brian Barnett, M.D., as Chief Executive Officer January 9, 2019